Amneal (NYSE: AMRX) CLO logs major RSU vesting, tax share withholdings

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. executive Jason B. Daly, EVP and Chief Legal Officer, reported multiple equity award vestings and related share movements in Class A Common Stock and restricted stock units.

On March 3, 2026, performance-based restricted stock units granted on March 3, 2023 were certified at 200% of the targeted number, resulting in the vesting and settlement of 305,810 performance-based restricted stock units into an equal number of Class A Common Stock shares on a one-for-one basis, with a portion of the resulting shares withheld to satisfy tax obligations. Additional time-based restricted stock units granted on March 3, 2022, March 3, 2023, March 4, 2024 and March 3, 2025 vested in scheduled installments and were converted into Class A Common Stock, again with some shares withheld for taxes.

Following these transactions, Daly held 251,784 shares of Class A Common Stock directly as of March 4, 2026, along with 71,760 restricted stock units, reflecting ongoing equity-based compensation rather than open-market purchases or sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly Jason B.

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/03/2026		M		22,645(1)	A	(2)	33,251	D
Class A Common Stock	03/03/2026		F		10,147(3)	D	$13.31	23,104	D
Class A Common Stock	03/03/2026		M		38,226(1)	A	(2)	61,330	D
Class A Common Stock	03/03/2026		F		16,598(3)	D	$13.31	44,732	D
Class A Common Stock	03/03/2026		M		24,258(1)	A	(2)	68,990	D
Class A Common Stock	03/03/2026		F		10,533(3)	D	$13.31	58,457	D
Class A Common Stock	03/03/2026		M		305,810	A	(4)	364,267	D
Class A Common Stock	03/03/2026		F		132,783(5)	D	$13.31	231,484	D
Class A Common Stock	03/04/2026		M		35,880(1)	A	(2)	267,364	D
Class A Common Stock	03/04/2026		F		15,580(3)	D	$13.3	251,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/03/2026		M			22,645	(6)	(6)	Class A Common Stock	22,645	$0	0	D
Restricted Stock Units	(2)	03/03/2026		M			38,226	(7)	(7)	Class A Common Stock	38,226	$0	38,227	D
Restricted Stock Units	(2)	03/03/2026		M			24,258	(8)	(8)	Class A Common Stock	24,258	$0	72,774	D
Performance-Based Restricted Stock Units	(4)	03/03/2026		M			305,810	(4)	(4)	Class A Common Stock	305,810	$0	0	D
Restricted Stock Units	(2)	03/04/2026		M			35,880	(9)	(9)	Class A Common Stock	35,880	$0	71,760	D

Explanation of Responses:

1. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

3. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

4. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

5. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.

6. On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

7. On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

8. On March 3, 2025, the reporting person was granted 97,032 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

9. On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AMRX executive Jason B. Daly report?

Jason B. Daly reported vesting and settlement of restricted stock units into Amneal Class A Common Stock, plus related tax-withholding share dispositions. These transactions reflect equity compensation mechanics rather than open-market buying or selling of shares by the executive.

How many AMRX performance-based restricted stock units vested for Jason B. Daly?

Jason B. Daly had 305,810 performance-based restricted stock units vest and settle into the same number of Class A Common Stock shares. These units were certified at 200% of the targeted amount after meeting average closing price performance conditions over a defined three-year period.

How many Amneal Class A shares does Jason B. Daly hold after these transactions?

After the reported transactions, Jason B. Daly directly held 251,784 shares of Amneal Class A Common Stock. This figure reflects shares received from vesting restricted stock units, net of those withheld to cover associated tax withholding obligations by delivering shares back to the issuer.

What happened to Jason B. Daly’s restricted stock units in the latest AMRX Form 4?

Several tranches of restricted stock units converted into Amneal Class A Common Stock as they vested. After these conversions and related tax withholding, Daly continued to hold 71,760 restricted stock units, representing additional contingent rights to receive shares over future vesting dates.

Were any AMRX shares sold on the open market in this Form 4?

The reported dispositions were shares withheld to satisfy tax withholding obligations tied to vesting restricted and performance-based units. Form 4 codes show tax-withholding dispositions rather than discretionary open-market sales initiated by Jason B. Daly through a brokerage transaction.

What equity award grants to Jason B. Daly are referenced in the AMRX filing?

The filing references restricted stock unit grants dated March 3, 2022, March 3, 2023, March 4, 2024, and March 3, 2025. These time-based awards vest in four equal installments beginning on the first anniversary of each grant date, delivering Class A Common Stock upon each vesting event.